"
Dalbavancin is a novel second-generation lipoglycopeptide agent that
belongs to the same class as vancomycin. Development of NOXAFIL is consistent with
Schering-Plough's strategy to broaden its anti-infectives portfolio and is in
line with its plans to build strength in its global franchises through both
internal research and external licensing opportunities. Safety and efficacy of repeated treatment or prophylaxis courses
have not been studied. 3 Best Company to Work For in
NJ (NJ Biz magazine), the No.cdc .

indic amare

"NOXAFIL, upon approval, will provide a new therapeutic option for
patients with serious infections caused by certain difficult-to-treat fungal
organisms, including those refractory to other drugs .

Roche Opens Full National Distribution for Seasonal Supply of Tamiflu(R)

S. Tamiflu treats flu at its source, by attacking the
virus that causes the flu, rather than simply masking symptoms. Frequently reported adverse events include nausea and
vomiting. An employer of choice, in 2005, Roche was named one of
Fortune magazine's Best Companies to Work For in America, one of the Top 20
Employers (Science magazine), ranked as the No.

ailments soranus

Food and Drug Administration (FDA) for the
New Drug Application (NDA) for its investigational agent dalbavancin, a novel
once-weekly antibiotic for the treatment of complicated skin and soft tissue
infections (cSSTIs) including the most difficult to treat strain of
staphylococcus, methicillin-resistant staphylococcus aureus (MRSA). Dalbavancin has been specifically designed as an
improved alternative to vancomycin. These approaches are yielding promising novel and next-
generation compounds, many of which are in the later stages of preclinical
development . Because of those risks,
Vicuron's actual results, performance or achievements may differ materially
from the results, performance or achievements contemplated by its forward-
looking statements . NOXAFIL co-
administration with ergot alkaloids, CYP3A4 substrates known to prolong the
QTc interval and HMG-CoA reductase inhibitors is contraindicated.
markets.
"We are prepared to meet seasonal demand for Tamiflu, including any
increase stemming from CDC's recent announcement," said George Abercrombie,
President and CEO, Hoffmann-La Roche Inc., based in Foster City, CA,
is a systemic treatment for the most common strains of influenza (types A and
B).com.

cures medicaments

, kills bacteria rather than merely inhibiting their growth). Vicuron's versatile
research engine integrates industry-leading expertise in functional genomics,
natural products discovery, mechanism-based drug design and combinatorial and
medicinal chemistry.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release
includes certain "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including statements relating to the
company's strategy and the potential regulatory approval for NOXAFIL.

1997;24:723-741, cited in Report 13 of the Council on Scientific Affairs (A-97 ), American Medical Assocation)

mehl russianfoods

Forward-Looking Statements
This news release contains forward-looking statements that predict or
describe future events or trends.S.schering-plough. Centers for Disease Control and
Prevention (CDC), which could potentially heighten demand for Tamiflu. In a
household prophylaxis trial that included patients one to 12 years old,
adverse events were consistent with those observed in pediatric treatment
studies, with GI events being the most frequently observed.
Tamiflu is available for the treatment of influenza in more than
80 countries worldwide .J.htm

Hufford, professor in the Department of Humanities at the Penn State College of Medicine:
Folk medicine is a form of complementary and alternative medicine that relies heavily (although not exclusively) on oral tradition.

pliny antifungal

Also Receives Acceptance to File Notification

KING OF PRUSSIA, Penn. aureus and certain other Gram-positive
bacteria. The information set forth in this news release represents
management's current expectations and intentions. Invasive fungal infections, which can be life threatening,
most often occur in people who are immunocompromised or immunosuppressed, such
as organ transplant patients or cancer patients undergoing either chemotherapy
or stem cell transplant. This will offer the
medical community in Europe an oral therapy for severely ill patients who are
struggling not only with their hematological malignancies but also with
difficult fungal infections requiring long-term treatment," said Raoul
Herbrecht, MD, professor and head of hematology in the Department of
Hematology and Oncology, University Hospital of Strasbourg, France .D.

The decision to open distribution is based on recent
developments, including increased flu reports from around the country and a
Health Alert issued last week by the U.S. (Roche), based in Nutley, N.

As stated by David J.

ailments abeba

The
potency, tissue penetration and half-life of dalbavancin may allow for more
convenient dosing regimens than vancomycin."

Study Results
The CHMP positive opinion is based primarily on data from a clinical study
evaluating NOXAFIL Oral Suspension 400 mg twice daily for the treatment of
invasive aspergillosis in patients with refractory disease or who were
intolerant of other medicinal products.flustar. The neuraminidase site is
virtually the same in the most common strains of influenza, types A and B.
In treatment studies in adult patients, the most frequently reported
adverse events (incidence >1%) were nausea and vomiting. Events reported more frequently in
patients taking Tamiflu compared with placebo (incidence >1%) were nausea ,
vomiting, diarrhea, abdominal pain, dizziness, headache and insomnia.gov/flu/keyfacts.

Merriam-Webster 's Collegiate Dictionary defines folk medicine as 'traditional medicine as practiced nonprofessionally especially by people isolated from modern medical services and usually involving the use of plant-derived remedies on an empirical basis'.

toenail medicaments

The matters described in these forward-
looking statements are subject to known and unknown risks, uncertainties and
other unpredictable factors, many of which are beyond Vicuron's control.

NOXAFIL, upon approval, would provide a new therapeutic option for
serious infections caused by aspergillosis, fusariosis, chromoblastomycosis,
mycetoma, and coccidioidomycosis .
Vaccination is considered the first line of defense against influenza.

About Roche
Hoffmann-La Roche Inc.S.

abeba mehl

The company's Web site is http://www.com. For further details about these and other factors that may impact
the forward-looking statements, see Schering-Plough's Securities and Exchange
Commission filings, including the company's second quarter 2005 10-Q."
FluSTAR (http://www.

How Tamiflu Works
Tamiflu works by targeting one of the two major surface structures of the
influenza virus, the neuraminidase protein. In treatment studies in
patients one to 12 years old, the most frequently reported adverse event
(incidence >1%) was vomiting.flustar .com) is gathered from
four different surveillance methods including rapid assay data,
laboratory confirmation and clinical diagnosis data.

amare abeba

S.
The NDA, which was submitted in December of last year, includes results
from more than 1,850 subjects and three Phase 3 trials that evaluated the
safety and efficacy of dalbavancin in patients with SSTIs caused by
Gram-positive bacteria., chief medical officer
and senior vice president of medical affairs, Schering-Plough Research
Institute." Actual results may vary materially from
the forward-looking statements, and there are no guarantees about the
performance of Schering-Plough stock or Schering-Plough's business., Roche announced today that it has
lifted all restrictions on the distribution of Tamiflu(R) (oseltamivir
phosphate) for seasonal orders and is now shipping product to all U. Other events reported more frequently in
patients taking Tamiflu compared with placebo included abdominal pain,
epistaxis , ear disorder and conjunctivitis.

ailments 723

European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole ) Oral Suspension for Treatment of Invasive Fungal Infections

, Schering-Plough Corporation
(NYSE: SGP) today reported that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive
opinion recommending approval of NOXAFIL(R) (posaconazole ) Oral Suspension for
the treatment of certain serious invasive fungal infections in adult patients
with refractory disease (failed prior therapy) or who are intolerant to other
therapy.
The CHMP recommendation of NOXAFIL serves as the basis for a European
Commission approval.

madrona 741

The reports that Vicuron files with the U.
"I am pleased that the CHMP has granted a positive opinion for
posaconazole in refractory invasive fungal infections.S.
The CDC announced that it now recommends against the use of two antiviral
medications, amantadine and rimantadine, for the remainder of the 2005-06
season, due to high levels of resistance, and that oseltamivir (Tamiflu) and
zanamivir (Relenza) should be prescribed if an antiviral medication is needed.

About Tamiflu
Tamiflu, co-developed by Gilead Sciences, Inc.roche.
(2) http://www.

mehl pliny

KENILWORTH, N. Approval of NOXAFIL in the
European Union would represent the first marketing approval for posaconazole,
a novel triazole antifungal agent discovered and developed by Schering-Plough
Research Institute. In this study, a successful response
(complete or partial resolution) at the end of treatment was seen in 42
percent (45 out of 107) of patients treated with NOXAFIL compared to 26
percent (22 out of 86) of patients in an external control group, as determined
by an independent data review committee . "We will continue to monitor the
evolving environment and do everything possible to effectively manage
inventory so that doctors and their patients can be assured that Tamiflu is
available to them for flu treatment and prevention.cdc.(2)
Stomach symptoms, such as nausea, vomiting, and diarrhea , can also occur but
are more common in children than adults.us.

medicaments ailments

, Vicuron
Pharmaceuticals Inc .e.

About Vicuron Pharmaceuticals
Vicuron Pharmaceuticals is a biopharmaceutical company focused on
discovering, developing, manufacturing and commercializing vital medicine for
seriously ill patients. Spiegel, M.com) is a comprehensive, nationwide network
developed to provide health care professionals and consumers with the most
up-to-date information on the spread of seasonal flu .

mehl hiccups

Securities and Exchange Commission contain a fuller description of these and
many other risks to which Vicuron is subject. NOXAFIL also
should be used with caution in patients with severe hepatic impairment. Schering-Plough's vision is to earn the trust of the
physicians, patients and customers served by its more than 30,000 people
around the world. Tamiflu is indicated for the treatment of uncomplicated influenza caused
by viruses types A and B in patients one year and older who have been
symptomatic for no more than two days.
pharmaceuticals headquarters of the Roche Group, one of the world's leading
research-oriented healthcare groups with core businesses in pharmaceuticals
and diagnostics.

hufford toothache

Food and Drug Administration for its lead products, dalbavancin,
a novel intravenous antibiotic for the treatment of serious Gram-positive
infections, and anidulafungin, a novel antifungal agent. In addition, the company has research collaborations with leading
pharmaceutical companies , such as Novartis and Pfizer.
Vicuron faces many risks that could cause its actual performance to differ
materially from the results predicted by its forward-looking statements,
including the possibilities that clinical trials and the results thereof might
be delayed or unsuccessful, that the timing of the filing of any new drug
application or any amendment to a new drug application might be delayed, that
clinical trials might indicate that a product candidate is unsafe or
ineffective , that the FDA might require additional information to be submitted
and additional actions to be taken before it will make any decision, that any
filed new drug application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield useful
results , that the pipeline may not yield a new clinical candidate or a
commercial product, that a third party may not be willing to license product
candidates on terms acceptable to it or at all, that competitors might develop
superior substitutes for Vicuron's products or market these competitive
products more effectively, that a sales force may not be developed as
contemplated and that one or more of Vicuron's product candidates may not be
commercialized successfully. cities
where high incidence of influenza was being reported, based on the FluSTAR
Surveillance System. No difference in the incidence of
complications was observed between the treatment and placebo groups in this
population.

noses hufford

(Nasdaq: MICU; Nuovo Mercato) announced today that the
company has received the acceptance to file notification and been granted
Priority Review status by the U.
Additional clinical data from this study demonstrated that patients with
invasive fungal infections caused by fusarium, agents of chromoblastomycosis
and mycetoma, and coccidioides were successfully treated with NOXAFIL. pharmaceuticals business, visit our websites: http://www.

(Hufford DJ.

'Folk medicine and health culture in contemporary society '.

madrona mehl

Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue Infections

The FDA
grants Priority designation to products which, if approved, would be a
significant improvement in the treatment of a disease. Horner III, President and CEO of
Vicuron . The external control group was
derived by retrospective review of medical records for patients with similar
diagnoses treated within the same timeframe as those in the NOXAFIL cohort. Forward-
looking statements relate to expectations or forecasts of future events and
use words such as "will" and "plans.
Many factors could cause actual results to differ from Schering-Plough's
forward-looking statements. These factors include uncertainties of the
regulatory approval and review process and difficulties in product
development.(1) According to
FluSTAR, which monitors flu regionally rather than by state borders, there is
high incidence of influenza in about half the country.
Roche implemented a proactive inventory management plan last fall,
following a huge spike in Tamiflu demand that was driven by fears of a
potential flu pandemic. If a patient suspects that he or she
may have influenza, it is important to see a physician within the first
48 hours of symptom onset, as the doctor may be able to prescribe an antiviral
medication to help reduce the flu's duration and severity.

stuffy abeba

Vicuron assumes no
responsibility to issue updates to the forward-looking matters discussed in
this news release. A Commission Decision will result in Marketing
Authorization with unified labeling that will be valid in the current EU 25
member states as well as in Iceland and Norway.

Roche had previously been distributing Tamiflu only to U. Influenza is widespread in
New York, Texas, Arizona, New Mexico, Nevada, Colorado, Kansas, and Wyoming.Tamiflu.com

or http://www.

colds pascalite

"We expect to commercialize dalbavancin by the first quarter of 2006
pending FDA approval. The Phase 3 clinical trials each met the primary and
secondary endpoints of non-inferiority when compared to linezolid, cefazolin
or vancomycin, three currently used agents for SSTIs.
In vitro studies have shown that in addition to being potent against
clinically important Gram-positive bacteria, dalbavancin is bactericidal
(i.J. Treatment-related serious adverse
events reported in patients with invasive fungal infections (1 percent each)
included increased hepatic enzymes, nausea, rash and vomiting.
Tamiflu attacks the influenza virus and is thought to work by stopping it from
spreading inside the body. Tamiflu is also indicated for the
prophylaxis of influenza in patients one year and older.
Treatment efficacy in subjects with chronic cardiac and/or respiratory
disease has not been established.

medicaments toothache

About NOXAFIL
NOXAFIL (posaconazole) Oral Suspension exhibits potent antifungal activity
in vitro against a wide range of fungal pathogens, including both yeasts and
moulds.S.rocheusa.

abeba medicaments

NOXAFIL Safety Information
Clinical studies have demonstrated that NOXAFIL Oral Suspension is
generally safe and well tolerated.S., is the U.

(1) Data for FluSTAR (http://www.

Primary Care.

cures antifungal

Vancomycin is one of the few
treatments available to hospital patients infected with difficult-to-treat
strains of Staphylococcus bacteria, or Staph known as MRSA
(methicillin-resistant Staphylococcus aureus) and MRSE (methicillin-resistant
Staphylococcus epidermidis ).S.
"A key challenge facing physicians in treating fungal infections today is
finding effective treatment options when patients do not respond to or cannot
tolerate initial therapy," said Robert J. The
safety and efficacy of NOXAFIL in patients below the age of 18 years have not
been established . Through
internal research and collaborations with partners, Schering-Plough discovers,
develops , manufactures and markets advanced drug therapies to meet important
medical needs. Schering-
Plough does not assume the obligation to update any forward-looking statement.gov/flu/weekly/fluactivity.htm ). Other events
reported numerically more frequently in patients taking Tamiflu compared with
placebo were bronchitis, insomnia and vertigo.
In prophylaxis studies in adult patients, adverse events were similar to
those seen in the treatment studies.
For more information visit http://www .

antifungal pascalite

The most common
pathogen isolated in these studies was S. aureus, with more than 400 patients
infected with MRSA. In preclinical studies,
dalbavancin appears to be one of the most potent antibiotics against MRSA,
including multiply drug-resistant S. The company has two New Drug Applications pending
with the U. The most frequently reported adverse
reactions reported in healthy volunteers and patients receiving NOXAFIL were
headache (8 percent) and nausea (6 percent).

Schering -Plough Corporation is a global science-based health care company
with leading prescription, consumer and animal health products. The CDC indicates that
22 states are currently reporting either widespread or regional activity
(http://www.

Flu Symptoms
The signs and symptoms of flu include high fever, headache, extreme
tiredness, dry cough, sore throat, runny or stuffy nose, and muscle aches. When taken
within two days of the onset of symptoms, Tamiflu can reduce the duration and
severity of the flu.
In post-marketing experience, rare cases of anaphylaxis and serious skin
reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and
erythema multiforme , have been reported with Tamiflu. For more than 100 years, the Roche Group has been committed
to developing innovative products and services that address prevention,
diagnosis and treatment of diseases , thus enhancing people's health and
quality of life. For additional information about
the U.

Strongly influenced by cultural norms and values, folk medicine generally comprises the 'unofficial' or 'lay ' health beliefs and practices found in all societies.

toenail russianfoods

"We are very pleased with this regulatory development which we believe
further demonstrates the serious underserved medical need that dalbavancin has
the potential to address," said George F. - Wider Flu Spread, CDC Health Alert Expected to Boost Demand -

NUTLEY, N.J. By temporarily halting some product shipments prior
to the 2005-06 flu season, Roche maintained the ability to distribute Tamiflu
to U. markets with confirmed influenza cases, while preserving a pipeline to
ensure continued availability. 1 Company to Sell For (Selling Power), and one
of AARP's Top Companies for Older Workers.